TFS Trial Form Support International and Karolinska University Hospital Prolong Partnership
TFS Trial Form Support International (TFS; Lund, Sweden) and Karolinska University Hospital, based in Stockholm, have extended their public-private partnership until 2016 and expanded the early clinical research facilities at the hospital's Karolinska Trial Alliance (KTA). An additional 16 beds have been added to the research unit, which mainly conducts microdosing, first-in-man (FIM), and proof of concept studies as well as PET imaging studies.
“With a total number of 30 beds, we now have extended our capacity which means that we can shorten timelines for certain studies by running more studies in parallel," said Eva Lundqvist, MSc, ML, Director Academic Alliances at TFS, in a company press release. "The expanded facility is a fully state-of-the-art equipped FIM research unit and has been designed so that it suits all different types of early clinical development studies."
With the additional space (850 square meters) and beds, TFS reports that KTA now has the largest Phase I unit in Northern Europe.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
